Genocea Provides First Quarter 2021 Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Genocea Biosciences (GNCA) Tops Q1 EPS by 3c
April 29, 2021 7:30 AM EDTGenocea Biosciences (NASDAQ: GNCA) reported Q1 EPS of ($0.17), $0.03 better than the analyst estimate of ($0.20).
Genocea continues to accumulate evidence that our ATLAS platform may enable immunotherapies that preferentially attack the surface-presented antigens driving anti-tumor responses or as we say, Targets Matter, said Chip Clark, Genoceas... More
